Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Lordick F., Shah M. A., Shitara K., Ajani J. A., Bang Y., Enzinger P. C., ...More

ANNALS OF ONCOLOGY, 2023 (SCI-Expanded, Scopus) identifier

  • Publication Type: Article / Abstract
  • Publication Date: 2023
  • Doi Number: 10.1016/j.annonc.2023.10.270
  • Journal Name: ANNALS OF ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
  • Bezmialem Vakıf University Affiliated: Yes